Uses of Spydmax 0.75 MIU

Spydmax 0.75 M.IU drug has the main active ingredient is Spiramycin, the drug is made in powder form, each package of Spydmax 0.75 M.IU contains 750,000 IU (0.75 million units) of Spiramycin.
Spiramycin belongs to the macrolide antibiotic group, the drug has antibacterial spectrum similar to the antibacterial spectrum of clindamycin and erythromycin. Spiramycin has a bacteriostatic effect on bacteria during the cell division phase. At serum concentrations, Spiramycin is bacteriostatic, however, when reaching concentrations in tissues, Spiramycin can be bactericidal. The mechanism of action of Spiramycin is to act on the 50S subunit of the bacterial ribosome, thereby preventing bacterial protein synthesis.
For populations with very low levels of resistance, Spiramycin is active against Gram-positive strains, Pneumococcus, Sfaphylococcus, Meningococcus, 75% of Streptococcus strains, most Gonococcus strains and Enterococcus. Strains of Bordetella pertussis, Corynebacteria, Actinomyces, Chlamydia, Mycoplasma and Toxoplasma are also susceptible to Spiramycin. However, this initial effect of Spiramycin was attenuated by widespread use of Erythromycin in Vietnam.
Spiramycin has no effect on Gram-negative intestinal bacteria. Bacterial resistance to Spiramycin has been reported, including cross-resistance between Spiramycin, Oleandomycin and Erythromycin. However, some strains resistant to Erythromycin are sometimes susceptible to Spiramycin.

2.1. Indications Spydmax 0.75 M.IU is indicated in the symptomatic treatment in the following cases:
Treatment of respiratory tract infections such as ENT, bronchopulmonary infections, skin and genital infections caused by bacteria sensitive to Spiramycin. Prophylactic treatment of meningococcal meningitis, when the patient has a contraindication to rifampicin. Prophylaxis of congenital toxoplasmosis during pregnancy. Prophylaxis of recurrent acute rheumatic fever in patients allergic to penicillin. 2.2.Contraindications Contraindicated to use Spydmax 0.75 M.IU in case of allergy or hypersensitivity to Spiramycin, Erythromycin or any excipient of Spydmax 0.75 M.IU.

3.1 Dosage of Spydmax 0.75 M.IU is taken orally, so patients can take the drug on an empty stomach for maximum therapeutic effect. Dosage of Spydmax 0.75 M.IU:
Adults: 6,000,000 - 9,000,000 IU, divided dose into 2 - 3 times/24 hours. In case of severe infection, a dose of up to 15,000,000 IU can be used, divided into several times a day. Children: 150,000 IU/kg/24 hours, divided dose into 3 times/day. Prophylactic treatment of Meningococcus meningitis:
Adults: 3,000,000 IU/time, once every 12 hours. Children: 75,000 IU/kg/time, once every 12 hours, for 5 days. Prophylaxis of congenital Toxoplasma infection during pregnancy: 9,000,000 IU/day, divided into several times a day, taking the drug for 3 weeks. 2 weeks apart for a repeat dose. Use in combination or alternately with Pyrimethamine/Sulfonamide regimen can achieve better treatment effect.
It should be noted: Patients using Spiramycin must comply with the treatment and take the drug for the full duration of the course of treatment.
3.2 Spydmax 0.75 M.IU overdose and management There are no reports of Spydmax 0.75 M.IU overdose.
3.3 Missing a dose of Spydmax 0.75 M.IU and handling If you forget to take a dose of Spydmax 0.75 M.IU take it as soon as possible. However, if it is close to the next dose of Spydmax 0.75 M.IU, skip the missed dose and take the next dose at the scheduled time. Do not take double the prescribed dose.

Use of Spiramycin rarely causes serious side effects.
Digestive: nausea, vomiting, diarrhea, dyspepsia, acute colitis. Body as a whole: fatigue, sweating, nosebleeds, feeling of pressure in the chest. Skin: urticaria, skin rash, exanthema, feeling like crawling ants. Rarely, anaphylactoid reactions or superinfections have been reported with long-term oral administration of Spiramycin. If any undesirable effects appear during the use of Spydmax 0.75 M.IU, the patient should notify the doctor for timely treatment.

Some notes when using Spydmax 0.75 M.IU:
Be careful when using the drug in patients with liver dysfunction, because Spiramycin can cause liver toxicity. Spydmax 0.75 M.IU has no influence on the ability to drive or use machines. Pregnancy: Spiramycin can cross the placenta, but the concentration of Spiramycin in the fetal blood is lower than in the mother's blood. Spiramycin does not cause adverse effects when used in pregnant women. To ensure safety, pregnant women should only use the drug when directed by a doctor. Lactation: Spiramycin may be excreted in human milk in high concentrations. Therefore, discontinue breastfeeding while taking Spydmax 0.75 M.IU.

Spiramycin reduces carpidopa absorption and levodopa concentrations when administered concomitantly. Oral contraceptives: Concomitant use with Spiramycin may reduce the effectiveness of oral contraceptives. There is an increased risk of ventricular arrhythmias when Spiramycin is co-administered with Stemizol, Cisapride and Terfenadine. Fluphenazine: The risk of dystonia is increased when used with Spiramycin. Spydmax 0.75 M.IU drug with the main ingredient is Spiramycin, the drug is used in the treatment of respiratory and skin infections caused by bacteria sensitive to Spiramycin. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.